FDA Inspection 1180597 — Amryt Pharmaceuticals, Inc.

Amryt Pharmaceuticals, Inc. — FEI 3009569098

The FDA completed an inspection of Amryt Pharmaceuticals, Inc. on September 14, 2022 in Boston, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
September 14, 2022
Fiscal Year
2022
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Boston, MA (United States)

Additional Details

Risk Evaluation and Mitigation Strategies (REMS)